New developments in the treatment of low high-density lipoprotein cholesterol

被引：3

作者：

Miller M. ^{[1
]}

机构：

[1] Division of Cardiology-Room S3B06, University of Maryland Medical System, 22 South Greene Street, Baltimore, 21201, MD

来源：

Current Atherosclerosis Reports | 1999年 / 1卷 / 1期

关键词：

Coronary Artery Disease Event; Coronary Drug Project; Fibrate Therapy; Helsinki Heart Study; Immediate Release;

D O I：

10.1007/s11883-999-0046-2

中图分类号：

学科分类号：

摘要：

Reduced levels of high-density lipoprotein (HDL) cholesterol represent an important risk factor for the development and progression of coronary artery disease. In recent years, clinical outcome studies have verified that statin therapy may reduce the risk of initial or recurrent cardiovascular events in subjects with elevated or “normal” cholesterol levels. Subgroup analysis has also revealed that patients with low HDL benefit from this therapy. Two recently presented outcome trials using fibrate therapy also demonstrated a potential role for these medications in subjects with low HDL. The use of various HDL raising agents, singly or in combination on arteriographic progression and their potential mechanisms of action are reviewed. The latter may be an important consideration in the treatment of high-risk patients with low HDL. © 1999, Current Science Inc.

引用

页码：24 / 30

页数：6

共 36 条

[1]

Miller G.J., Miller N.E., Plasma high-density lipoprotein concentration and development of ischaemic heart disease, Lancet, 1, pp. 16-19, (1975)

[2]

Miller M., Mead L.A., Kwiterovich P.O., Pearson T.A., Dyslipidemias with desirable total cholesterol and arteriographically demonstrated coronary disease, Am J Cardiol, 65, pp. 1-5, (1990)

[3]

Miller M., Seidler A., Kwiterovich P.O., Pearson T.A., Long-term predictors of subsequent cardiovascular events with coronary artery disease and desirable levels of plasma total cholesterol, Circulation, 86, pp. 1165-1170, (1992)

[4]

Frick M.H., Elo O., Haapa K., Et al., The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of coronary heart disease, N Engl J Med, 317, pp. 1237-1245, (1987)

[5]

Goldbourt U., Behar S., Reicher-Reiss H., Et al., Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial), Am J Cardiol, 71, pp. 909-915, (1993)

[6]

Ericsson C.-G., Hamsten A., Nilsson J., Et al., Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet, 347, pp. 849-853, (1996)

[7]

Goldbourt U., Brunner D., Behar S., Reicher-Reiss H., Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study, Eur Heart J, 19, pp. H42-H47, (1998)

[8]

Frick M.H., Syvanne M., Nieminen M.S., Et al., Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation, 96, pp. 2137-2143, (1997)

[9]

Shepherd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, pp. 1301-1307, (1995)

[10]

Downs J.R., Clearfield M., Weis S., Et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 279, pp. 1615-1622, (1998)

← 1 2 3 4 →